|
|
|
|
|||||
|
|
|
Thermo Fisher Scientific Inc. TMO recently launched the Thermo Scientific Orbitrap Astral Zoom mass spectrometer (MS) and the Thermo Scientific Orbitrap Excedion Pro MS at the American Society for Mass Spectrometry’s annual conference in Baltimore, MD. The instruments are built to reveal intricate biological mechanisms that may drive progress in precision medicine and offer valuable insights into complex diseases, such as Alzheimer’s and cancer.
The latest launch enhances Thermo Fisher’s industry-leading Life Sciences Solutions portfolio.
After the announcement yesterday, TMO shares lost 1.6%, closing at $396.47.
On a positive note, in recent years, Thermo Fisher has gradually ramped up investment in R&D. The company is launching a slew of products, enhancing its portfolio. Henceforth, we expect that the latest launch will positively boost the market sentiment toward TMO stock in the upcoming days.
Presently, Thermo Fisher boasts a market capitalization of $149.67 billion. The Zacks Consensus Estimate forecasts a 2.1% increase in the company’s earnings and 1.9% growth in revenues, both on a year-over-year basis. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.3%.
Expanding on the success of the Thermo Scientific Orbitrap Astral mass spectrometer, the Orbitrap Astral Zoom MS delivers unparalleled performance and is engineered to drive the next wave of breakthroughs in scientific research. The instrument enables 35% faster scan speeds, 40% higher throughput and 50% expanded multiplexing capabilities, delivering higher sensitivity and increased experimental flexibility.
The Thermo Scientific Orbitrap Excedion Pro MS offers enhanced performance to accelerate biological drug development. The Orbitrap Excedion Pro is the first platform to combine next-generation Orbitrap hybrid mass spectrometry with alternative fragmentation technologies, a technique for efficiently analyzing complex biomolecules. With enhanced sensitivity, dynamic range and reliability, the Orbitrap Excedion Pro MS delivers faster, higher-quality protein and post-translational modification data along with small molecule insights to drive robust biological understandings.
Per a report by Grand View Research, the global mass spectrometry market size is projected to witness a compound annual growth rate of 8% from 2025 to 2030. Increasing R&D in the pharmaceutical and biotechnology industries is expected to drive the adoption of mass spectrometers. Moreover, advancements in proteomics research and the rapid growth of biomedical research are other factors contributing to market growth.
Thermo Fisher recently unveiled its latest innovation, the spectral-enabled Invitrogen Attune Xenith Flow Cytometer. The solution allows immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples.
In the past year, TMO shares have plunged 30.4% compared with the industry’s 12.2% decline.
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry’s 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry’s 0.5% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company’s 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
Estimates for Prestige Consumer Healthcare’s fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry’s 10.1% growth. PBH’s earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 1 hour | |
| 3 hours | |
| 4 hours | |
| 7 hours | |
| 8 hours | |
| 8 hours | |
| 8 hours | |
| 9 hours | |
| 9 hours | |
| 9 hours | |
| 10 hours | |
| 11 hours | |
| 11 hours | |
| 14 hours | |
| Jun-24 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite